Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

A Basu, G Ramamoorthi, G Albert, C Gallen… - Frontiers in …, 2021 - frontiersin.org
Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

Therapy-induced senescence: an “old” friend becomes the enemy

T Saleh, S Bloukh, VJ Carpenter, E Alwohoush… - Cancers, 2020 - mdpi.com
For the past two decades, cellular senescence has been recognized as a central component
of the tumor cell response to chemotherapy and radiation. Traditionally, this form of …

Targeting senescence as an anticancer therapy

L Bousset, J Gil - Molecular Oncology, 2022 - Wiley Online Library
Cellular senescence is a stress response elicited by different molecular insults. Senescence
results in cell cycle exit and is characterised by multiple phenotypic changes such as the …

Therapy-induced senescence as a component of tumor biology: Evidence from clinical cancer

T Saleh, S Bloukh, M Hasan, S Al Shboul - Biochimica et Biophysica Acta …, 2023 - Elsevier
Abstract Therapy-Induced Senescence (TIS) is an established response to anticancer
therapy in a variety of cancer models. Ample evidence has characterized the triggers …

Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival

CA Tonnessen-Murray, WD Frey, SG Rao… - Journal of Cell …, 2019 - rupress.org
In chemotherapy-treated breast cancer, wild-type p53 preferentially induces senescence
over apoptosis, resulting in a persisting cell population constituting residual disease that …

Senescence-associated secretory phenotype as a hinge between cardiovascular diseases and cancer

P Banerjee, S Kotla, L Reddy Velatooru… - Frontiers in …, 2021 - frontiersin.org
Overlap** risks for cancer and cardiovascular diseases (CVD), the two leading causes of
mortality worldwide, suggest a shared biology between these diseases. The role of …

[HTML][HTML] Neoantigen-specific Cd4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic Melanoma patients

MLS Hall, JK Teer, X Yu, H Branthoover… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a
promising immunotherapeutic approach for patients with advanced solid tumors. While …

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Y Zhou, L Tao, J Qiu, J Xu, X Yang, Y Zhang… - … and Targeted Therapy, 2024 - nature.com
Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …

Cytokine-induced senescence in the tumor microenvironment and its effects on anti-tumor immune responses

M Rentschler, H Braumüller, PS Briquez, T Wieder - Cancers, 2022 - mdpi.com
Simple Summary Despite tremendous treatment efforts, cancer is still one of the leading
causes of death, with approximately 10 million deaths in 2020. In the last decade …

[HTML][HTML] Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway

Y Jia, KN Kodumudi, G Ramamoorthi, A Basu… - Molecular Therapy, 2021 - cell.com
HER2 breast cancer (BC) remains a significant problem in patients with locally advanced or
metastatic BC. We investigated the relationship between T helper 1 (Th1) immune response …